NasdaqGS - Delayed Quote • USD
CytomX Therapeutics, Inc. (CTMX)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 5 | 6 | 6 |
| Avg. Estimate | -0.06 | -0.04 | -0.28 | -0.42 |
| Low Estimate | -0.22 | -0.15 | -0.75 | -1.11 |
| High Estimate | 0.02 | 0.01 | 0.04 | -0.12 |
| Year Ago EPS | -0.05 | -0.02 | -0.01 | -0.28 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 5 | 6 |
| Avg. Estimate | 22.02M | 21.43M | 88.44M | 77.9M |
| Low Estimate | 15M | 11M | 80M | 26M |
| High Estimate | 27M | 27M | 108M | 108M |
| Year Ago Sales | 23.5M | -- | 101.21M | 88.44M |
| Sales Growth (year/est) | -6.30% | -- | -12.60% | -11.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.11 | -0.2 | -0.19 | -0.03 |
| EPS Actual | -0.05 | -0.02 | 0.04 | 0.01 |
| Difference | 0.06 | 0.18 | 0.23 | 0.04 |
| Surprise % | 54.50% | 90.00% | 121.10% | 133.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.06 | -0.04 | -0.28 | -0.42 |
| 7 Days Ago | -0.05 | -0.02 | -0.19 | -0.37 |
| 30 Days Ago | -0.07 | -0.02 | -0.24 | -0.37 |
| 60 Days Ago | 0 | -0.01 | -0.19 | -0.27 |
| 90 Days Ago | -0.03 | -0.03 | -0.23 | -0.27 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CTMX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -20.00% | -- | -- | 2.60% |
| Next Qtr. | -100.00% | -- | -- | 13.40% |
| Current Year | -2,700.00% | -- | -- | 5.20% |
| Next Year | -50.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -0.90% | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | JP Morgan: Underweight to Neutral | 4/22/2024 |
| Maintains | BMO Capital: Market Perform to Market Perform | 3/12/2024 |
| Reiterates | Wedbush: Neutral to Neutral | 3/12/2024 |
| Maintains | Wedbush: Neutral to Neutral | 11/9/2023 |
| Upgrade | Wedbush: Neutral to Outperform | 11/8/2023 |
| Maintains | BMO Capital: Market Perform to Market Perform | 8/9/2023 |
Related Tickers
ASMB Assembly Biosciences, Inc.
13.36
-0.67%
SPRO Spero Therapeutics, Inc.
1.4300
+0.70%
EIGRQ Eiger BioPharmaceuticals, Inc.
3.0400
-19.95%
TIL Instil Bio, Inc.
10.40
-1.89%
NXTC NextCure, Inc.
1.2900
-10.42%
CLRB Cellectar Biosciences, Inc.
3.0200
-1.31%
GLPG.AS Galapagos NV
26.56
-2.06%
ALGS Aligos Therapeutics, Inc.
0.8180
-1.33%
PRTC.L PureTech Health plc
212.50
0.00%
PRTC PureTech Health plc
27.33
-5.27%